CTChristelle Tesson

Christelle Tesson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christelle Tesson has a total of 249 co-authors. Here are the top co-authors by number of shared publications:

  • Alexis Brice

    Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Recherche Médicale-U1127, Centre National de la Recherche Scientifique-UMR7225, APHP, Paris, France

    7 shared publications
  • Suzanne Lesage

    Sorbonne Université, Institut du Cerveau—Paris Brain Institute—ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Hôpital Pitié‐Salpêtrière Paris France

    7 shared publications
  • Guillaume Cogan

    Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Recherche Médicale-U1127, Centre National de la Recherche Scientifique-UMR7225, APHP, Paris, France

    6 shared publications
  • Alexis Brice

    Sorbonne Université, Institut du Cerveau ‐ Paris Brain Institute ‐ ICM, Institut National de la Recherche Médicale‐U1127, Centre National de la Recherche Scientifique‐UMR7225, APHP Paris France

    4 shared publications
  • Suzanne Lesage

    Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France

    4 shared publications
  • Ana Marques

    Neurology Department, Université Clermont Auvergne, EA7280 NPsy-Sydo, Clermont-Ferrand University Hospital, France; and

    3 shared publications

Latest Publications

  • Open Access

    Investigation of Parkinsonism‐Associated Genes in a Large Cohort of Individuals with Early‐Onset or Familial Predominant Parkinsonism

    by Kilian Rousvoal, Guillaume Cogan, Christelle Tesson, Lionel Arnaud, Matheus Gomes Ferreira, Salmo Raskin, Guilherme Lourenço de Macedo, Sarah Meftahi, Emmanuel Roze, Louise‐Laure Mariani, et al.

    Background: A study of a large cohort, including early‐onset or familial patients with Parkinson's disease (PD), has deciphered the contribution of known PD genes. However, many other genes, thereafter labeled parkinsonism‐associated genes (PAG), are associated with other neurological conditions in which parkinsonism is sometimes reported. Objective: The aim was to evaluate the contribution of these genes in patients with predominant parkinsonism. Methods: We performed whole‐exome sequencing in a cohort of 1488 probands with early‐onset (here defined by an age at onset GBA1 , LRRK2 , PARK7 , PINK1 , PRKN , SNCA , VPS35 ). One hundred eighteen PAGs were selected for the analysis based on their assessment by experts in three different consortia (Genomics England PanelApp , PanelApp Australia, International Genetic Nomenclature in Movement Disorders Study Group). Pathogenic variants were extracted from these genes according to the criteria of the American College of Medical Genetics. Results: Eighty‐one probands (5.4%) carried a pathogenic variant of one PAG. Clinical review (available for 71/81 probands) revealed that the phenotype was compatible with the variant in 91.5% (65/71) of probands. Thirty‐seven genes were considered disease causing. Among them, six ( ATP13A2 , ATXN2 , FIG4 , GCH1 , PLA2G6 , PPP2R5D ) accounted for a large proportion of probands with a compatible phenotype (26/65, 40.0%). Conclusions: Our results indicate that PAGs would account for about 5% of patients with early‐onset or familial predominant parkinsonism not mutated for known PD genes, and that clinical evaluation is essential to establish causality. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Building Scalable Recruitment Models for Precision Medicine in Parkinson's Disease: Insights from GBA1 Trials

    by Jean‐Christophe Corvol, Christelle Tesson, Sophie Liot, Stéphanie Carvalho, Giovanni Castelnovo, Philippe Damier, Luc Defebvre, Caroline Giordana, Jean‐Luc Houeto, Ana Marques, et al.

  • Exploring the genetic spectrum of parkinsonism in Brazil

    by Matheus G. Ferreira, Christelle Tesson, Thomas Courtin, Guilherme Lourenço de Macedo, Renata Barreto Tenório, Salmo Raskin, Suzanne Lesage, Alexis Brice, Hélio A.G. Teive

  • Open Access

    Parkinson’s disease and multiple system atrophy are gateways to RFC1 -related disorders

    by Violette Delforge, Giulia Coarelli, Eugenie Mutez, Anne-Sophie Rolland, Anna Wissocq, Amelie Labudeck, Christianne Marzys, Nazha Boucetta, Luc Buee, David Blum, et al.

    Biallelic pathogenic expansions of the RFC1 gene are the genetic cause of cerebellar ataxia, neuropathy, and bilateral vestibular areflexia syndrome. Sensory neuropathy is the most common symptom, but the clinical impairments and gateways to RFC1 -related diseases are extremely variable. We genotyped patients with parkinsonism to test the hypothesis that this condition is another such gateway. We screened four cohorts of patients with parkinsonism ( n = 2037) for pathogenic expansions in the RFC1 gene. In patients bearing two pathogenic expansions, we excluded the possibility of other pathogenic variants by exome sequencing. We detected 10/2037 (0.5%) biallelic (AAGGG) n RFC1 expansions. The initial diagnosis was Parkinson’s disease in five patients, multiple system atrophy in three and atypical parkinsonism in two. Phenotypes perfectly mimicking Parkinson’s disease and multiple system atrophy defined according to the international diagnostic criteria may serve as gateways to some RFC1 -related disorders. These results could modify the diagnostic and management of these two diseases. The diagnosis and follow-up of patients with parkinsonism should include searches for typical features evocative of a RFC1 -relative disease, such as sensory neuropathy or chronic cough. Nerve conduction studies should be conducted in patients with unexplained symptoms of neuropathic pain or sensory neuropathy. We also suggest that RFC1 screening should be performed in patients with atypical parkinsonism or multiple system atrophy with a long survival. Trial Registration Information: The PREDISTIM cohort is registered with ClinicalTrials.gov : NCT02360683 Graphical MSA = multiple system atrophy; PD = Parkinson’s disease; RFC1 = replication factor C subunit 1

  • Open Access

    Screening of Hidden Pathogenic Structural Variants in PRKN

    by Kensuke Daida, Guillaume Cogan, Christelle Tesson, Suzanne Lesage, Susen Schaake, Alexander Balck, Joanne Trinh, Katja Lohmann, Laksh Malik, Breeana Baker, et al.


  • A PARK7 Mutation‐Induced Early‐Onset Parkinson's Disease in a Moroccan Family: Expanding the Geographic Spectrum

    by Hicham El Otmani, Christelle Tesson, Alexis Brice, Suzanne Lesage

    Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and nonmotor symptoms, with a significant genetic component. Early‐onset Parkinson's disease (EOPD), manifesting before age 45, is often linked to mutations in genes such as PARK2, PINK1, and PARK7, the latter coding for the protein DJ‐1.Objective: We present the first reported cases of EOPD carrying a previously undescribed homozygous PARK7 mutation, p.Thr110Pro.Methods: Whole exom sequencing was performed on two inbred Moroccan siblings with early‐onset Parkinson's disease (EOPD). Detailed clinical assessments, including neurological evaluations and cognitive testing, were conducted to understand the clinical presentation of the patients. Genetic analysis was also carried out to examine their genetic background. Therapeutic responses to treatments were monitored to assess the effectiveness of management strategies.Results: The sequencing revealed that both siblings carried the homozygous PARK7 mutation, p.Thr110Pro. Both siblings presented with typical EOPD features, including motor and non‐motor symptoms. The patients both presented with cognitive impairment, with the male sibling exhibiting more pronounced symptoms. He also developed compulsive behaviors, which underscore the varied clinical presentations and therapeutic responses associated with this genetic variant.Conclusion: This case study expands the genetic and geographic diversity of PD presentations, highlighting cognitive and behavioral challenges and variable therapeutic outcomes. It underscores the necessity for genetic screening and individualized management strategies for patients with PD.


  • Open Access

    Confirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease

    by Guillaume Cogan, Christelle Tesson, Christine Brefel‐Courbon, Aymeric Lanore, Gatepe Cedoine Kodjovi, Lisa Welment, Fabienne Clot, Suzanne Lesage, Alexis Brice


  • Open Access

    Long‐Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early‐Onset Parkinson's Disease

    by Guillaume Cogan, Kensuke Daida, Kimberley J. Billingsley, Christelle Tesson, Sylvie Forlani, Ludmila Jornea, Lionel Arnaud, Laurène Tissier, Eric LeGuern, Andrew B. Singleton, et al.


  • Open Access

    Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from early-onset Parkinson’s disease to perinatal lethality and disrupt mitochondrial function

    by Francesca Magrinelli, Christelle Tesson, Plamena R. Angelova, Jose A. Rodriguez, Annarita Scardamaglia, Benjamin O’callaghan, Simon A. Lowe, Ainara Salazar-Villacorta, Brian Hon-Yin Chung, Matthew Jaconelli, et al.

    Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson’s disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here, we identify PSMF1 as a novel gene implicated in parkinsonism and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD to perinatal lethality with neurological manifestations across 17 pedigrees with 24 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/PI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants impair mitochondrial membrane potential, dynamics and mitophagy, and may affect proteasomal abundance and assembly in patient-derived fibroblasts. Furthermore, Drosophila and mouse models of PSMF1 loss of function exhibit age-dependent motor impairment, as well as brain-wide mitochondrial membrane depolarization and dopaminergic neurodegeneration in aged flies, and diffuse gliosis in mice. Collectively, our findings unequivocally link defective PSMF1 to early-onset parkinsonism and neurodegeneration, and suggest proteasomal and mitochondrial dysfunction as mechanistic contributors.


  • Open Access

    Long-read sequencing unravels the complexity of structural variants in PRKN in two individuals with early-onset Parkinson’s disease

    by Guillaume Cogan, Kensuke Daida, Kimberley J. Billingsley, Christelle Tesson, Sylvie Forlani, Ludmila Jornea, Lionel Arnaud, Laurene Tissier, Eric LeGuern, Andrew B. Singleton, et al.

    Background: PRKN biallelic pathogenic variants are the most common cause of autosomal recessive early-onset Parkinson’s disease (PD). However, the variants responsible for suspected PRKN- PD individuals are not always identified with standard genetic testing. Objectives: Identify the genetic cause in two siblings with a PRKN -PD phenotype using long-read sequencing (LRS). Methods: The genetic investigation involved standard testing using successively multiple ligation probe amplification (MLPA), Sanger sequencing, targeted sequencing, whole-exome sequencing and LRS. Results: MLPA and targeted sequencing identified one copy of exon four in PRKN but no other variants were identified. Subsequently, LRS unveiled a large deletion encompassing exon 3 to 4 on one allele and a duplication of exon 3 on the second allele; explaining the siblings’ phenotype. MLPA could not identify the balanced rearrangement of exon 3. Conclusions: This study highlights the potential utility of long-read sequencing in the context of unsolved typical PRKN- PD individuals.